Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics
Oxford, UK, 14 July 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’) – a pioneering biotechnology company unlocking the therapeutic potential of the regulatory genome through its proprietary 3D genomics platform – announces that the United States Patent & Trademark Office (USPTO) has granted US patent number US12,674,197 entitled “Process for producing a chromatin conformation capture (3C) library”.
